Sheela Tejwani

2.2k total citations · 2 hit papers
23 papers, 1.7k citations indexed

About

Sheela Tejwani is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Sheela Tejwani has authored 23 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Sheela Tejwani's work include Prostate Cancer Treatment and Research (10 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Sheela Tejwani is often cited by papers focused on Prostate Cancer Treatment and Research (10 papers), Radiopharmaceutical Chemistry and Applications (6 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Sheela Tejwani collaborates with scholars based in United States, Australia and United Kingdom. Sheela Tejwani's co-authors include Susan F. Slovin, Celestia S. Higano, Tomasz M. Beer, Howard I. Scher, Andrea Harzstark, Omid Hamid, Kevin M. Chin, Joshi J. Alumkal, Paul Gagnier and M. Brent McHenry and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Sheela Tejwani

21 papers receiving 1.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500

2014 482 citations Jeffrey B. Smerage, William E. Barlow et al. Journal of Clinical Oncology profile →
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

2013 436 citations Susan F. Slovin, Celestia S. Higano et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sheela Tejwani United States	12	1.1k	633	529	458	348	23	1.7k
Carminia Maria Della Corte Italy	26	1.5k 1.3×	476 0.8×	716 1.4×	430 0.9×	1.3k 3.7×	78	2.6k
Qingyuan Zhang China	22	1.3k 1.2×	252 0.4×	617 1.2×	331 0.7×	376 1.1×	76	1.9k
Chenyue Zhang China	22	578 0.5×	198 0.3×	303 0.6×	465 1.0×	680 2.0×	74	1.4k
Qiuyi Huang China	16	906 0.8×	304 0.5×	435 0.8×	566 1.2×	965 2.8×	32	1.8k
Stefan C. Grant United States	22	786 0.7×	292 0.5×	372 0.7×	176 0.4×	524 1.5×	45	1.4k
Chiara Ciccarese Italy	23	803 0.7×	192 0.3×	1.1k 2.1×	681 1.5×	863 2.5×	116	2.1k
Fazong Wu China	17	241 0.2×	189 0.3×	256 0.5×	333 0.7×	507 1.5×	38	1.0k
Yitao Gong China	11	787 0.7×	239 0.4×	392 0.7×	504 1.1×	859 2.5×	27	1.6k
Zhengtang Chen China	24	813 0.7×	345 0.5×	196 0.4×	396 0.9×	835 2.4×	49	1.6k

Countries citing papers authored by Sheela Tejwani

Since Specialization

Citations

This map shows the geographic impact of Sheela Tejwani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheela Tejwani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheela Tejwani more than expected).

Fields of papers citing papers by Sheela Tejwani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sheela Tejwani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheela Tejwani. The network helps show where Sheela Tejwani may publish in the future.

Co-authorship network of co-authors of Sheela Tejwani

This figure shows the co-authorship network connecting the top 25 collaborators of Sheela Tejwani. A scholar is included among the top collaborators of Sheela Tejwani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sheela Tejwani. Sheela Tejwani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Suleiman, Noor, et al.. (2023). A Case of Immune-Mediated Pneumonitis Associated With Dual Nivolumab and Ipilimumab Immunotherapy Treatment. Cureus. 15(6). e40792–e40792.

Vaishampayan, Ulka N., Lance K. Heilbrun, Paul Monk, et al.. (2021). Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer. JAMA Network Open. 4(1). e2034633–e2034633. 28 indexed citations

Tejwani, Sheela, et al.. (2018). SAPHO Syndrome Masquerading as Metastatic Breast Cancer. SHILAP Revista de lepidopterología. 2018. 1–5. 2 indexed citations

Chowdhury, S., Ray McDermott, Josep M. Piulats, et al.. (2018). Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 29. viii273–viii273. 3 indexed citations

Vaishampayan, Ulka N., Lance K. Heilbrun, Paul Monk, et al.. (2018). Randomized trial of enzalutamide versus bicalutamide in combination with androgen deprivation in metastatic hormone sensitive prostate cancer: A Prostate Cancer Clinical Trials Consortium trial.. Journal of Clinical Oncology. 36(6_suppl). 190–190. 1 indexed citations

Jain, Raka, et al.. (2015). Longitudinally extensive transverse myelitis as presenting manifestation of small cell carcinoma lung. Oxford Medical Case Reports. 2015(2). 208–210. 5 indexed citations

Smerage, Jeffrey B., William E. Barlow, Gabriel N. Hortobágyi, et al.. (2014). Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. Journal of Clinical Oncology. 32(31). 3483–3489. 482 indexed citations breakdown →

Slovin, Susan F., Celestia S. Higano, Omid Hamid, et al.. (2013). Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Annals of Oncology. 24(7). 1813–1821. 436 indexed citations breakdown →

Sarantopoulos, John, Antje Hoering, Timothy W. Synold, et al.. (2012). Phase I pharmacokinetic study of dasatinib (BMS-354825) in patients with advanced malignancies and varying levels of liver dysfunction: S0711, a SWOG early therapeutics committee study.. Journal of Clinical Oncology. 30(15_suppl). 3078–3078. 1 indexed citations

10.

Slovin, Susan F., Omid Hamid, Sheela Tejwani, et al.. (2012). Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study.. Journal of Clinical Oncology. 30(5_suppl). 25–25. 12 indexed citations

11.

Tejwani, Sheela, Lance K. Heilbrun, Joseph A. Fontana, et al.. (2012). Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer. ISRN Oncology. 2012. 1–7. 14 indexed citations

12.

Tejwani, Sheela, Lance K. Heilbrun, Joseph A. Fontana, et al.. (2011). Phase II trial of bevacizumab monotherapy in nonmetastatic castrate-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 29(7_suppl). 33–33. 2 indexed citations

13.

Slovin, Susan F., Tomasz M. Beer, Celestia S. Higano, et al.. (2009). Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 27(15_suppl). 5138–5138. 45 indexed citations

14.

Tejwani, Sheela, et al.. (2009). Ischemic myositis in a diabetic patient receiving chemotherapy. Community Oncology. 6(2). 69–79. 3 indexed citations

15.

Tejwani, Sheela, et al.. (2008). Cardiotoxicity with fluorouracil and capecitabine revisited. Community Oncology. 5(10). 566–568.

16.

Kaseb, Ahmed O., Kannagi Chinnakannu, Di Chen, et al.. (2007). Androgen Receptor– and E2F-1–Targeted Thymoquinone Therapy for Hormone-Refractory Prostate Cancer. Cancer Research. 67(16). 7782–7788. 177 indexed citations

17.

Kaseb, Ahmed O., Sheela Tejwani, George Divine, et al.. (2007). Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine. Proceedings of the National Academy of Sciences. 104(7). 2343–2348. 24 indexed citations

18.

Rogers, Lisa R., et al.. (2004). Durable response of breast cancer leptomeningeal metastasis tocapecitabine monotherapy. Neuro-Oncology. 6(1). 63–64. 60 indexed citations

19.

Abou‐Issa, Hussein, et al.. (1995). Relative efficacy of glucarate on the initiation and promotion phases of rat mammary carcinogenesis.. PubMed. 15(3). 805–10. 26 indexed citations

20.

Tejwani, Sheela, et al.. (1987). Immune hemolytic anemia associated with ketoconazole therapy.. PubMed. 6(6). 499–500. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact